# US 2026/0232658 A1 · Azetidinyl benzoxazole compounds and their use as mer and axl inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0232658 A1
- Document ID: US20260232658A1
- Status: Published application
- Kind: A1
- Application number: 19/122,199
- Filed: 2023-10-20
- Published: 2026-08-13
- Earliest claimed: 2022-10-20
- Assignees: Dong-A St Co., Ltd.
- Applicants: Dong-A St Co., Ltd.
- Inventors: Robin R. FREY; Zhiqin JI; Yujia DAI; Julie M. MIYASHIRO; Thomas D. PENNING
- Web page: https://patentgrep.com/patent/US20260232658A1

## CPC

- A61K 31/497: containing further heterocyclic rings
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- C07D 413/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07F 9/65324: {condensed with carbocyclic rings or carbocyclic ring systems}
- C07F 9/65583: {each of the hetero rings containing nitrogen as ring hetero atom}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

Compounds of formula (I) and an enantiomer, a diastereomer, a racemate, a tautomer, a prodrug, a hydrate, a solvate and pharmaceutically acceptable salts thereof, wherein L, R1, R2, R3 and W, are as defined in the specification, are useful in the treatment of diseases and conditions influenced by inhibition of Mer kinase, including cancer.

## Claims

### Claim 1

A compound of formula (I), or an enantiomer, a diastereomer, a racemate, a tautomer, a prodrug, a hydrate, a solvate or a pharmaceutically acceptable salt thereof:
where
W is N or CH;
L is selected from the group consisting of a bond, —CH═CHCRaRb—, —(CRaRb)n—O—, —(CRaRb)n—C(O)—, —O—, —O—(CRaRb)n—, —O—(CRaRb)n—O—, —OCH2C(O)—, and —C(O)—;
each Ra is independently selected from the group consisting of hydrogen, C1-C4 alkyl, and C1-C2 hydroxyalkyl;
each Rb is independently selected from the group consisting of hydrogen and C1-C4 alkyl;
where Ra and Rb optionally combine to form a C3-6 cycloalkyl or 3-6 membered heterocycle;
R1 is selected from the group consisting of H, C1-C6 alkyl, and 5-6 membered heterocyclyl; wherein the R1 C1-C6 alkyl is optionally substituted with 1 or 2 R4;
R2 is selected from the group consisting of hydrogen, fluoro, chloro, bromo, and C1-C4 alkyl;
R3 is selected from the group consisting of hydrogen, fluoro, chloro, bromo, —CN, C1-C4 alkyl, C1-C4 haloalkyl, —OH, —OR3a, —NR3bR3c, —P(O)(OR3d)2, —C(O)CHR3eNR3bR3c, —C(O)OH, —C(O)OR3a, —C(O)NR3bR3c, C3-C8 cycloalkyl, C5-C7 cycloalkenyl, 3-6 membered heterocyclyl, C5-C7 heterocycloalkenyl, C6 aryl, 5-6 membered heteroaryl and
wherein the C3-C8 cycloalkyl, C6 aryl, 3-6 membered heterocyclyl, and 5-6 membered heteroaryl of R3, are optionally substituted with 1 or 2 of R5;
R3a is C1-C4 alkyl;
R3b and R3c are each independently selected from the group consisting of hydrogen, C1-C4 alkyl, C3-C6 cycloalkyl, and —CO2R3f;
R3d is selected from the group consisting of hydrogen, C1-C4 alkyl, and C2-C4 alkenyl;
R3e is selected from the group consisting of hydrogen and C1-C4 alkyl; wherein the C1-C4 alkyl of R3e is optionally substituted with 1 of R3g;
R3f is C1-C4 alkyl;
R3g selected from the group consisting of —OH, —SH, —SCH3, —NH2, —C(O)OH, —C(O)NH2, —NHC(NH)NH2, C6 aryl, and 5-9 membered heteroaryl; wherein the C6 aryl of R3g is optionally substituted with 1 of —OH;
R4 is selected from the group consisting of —OH, —OR4a, —C(O)NR4bR4c, and 5-6 membered heterocyclyl; wherein the 5-6 membered heterocyclyl of R4 is optionally substituted with 1 or 2 of C1-C4 alkyl;
R4a is C1-C4 alkyl; wherein the C1-C4 alkyl of R4a is optionally substituted with 1-Si(R4d)3;
R4b and R4c are each independently selected from the group consisting of hydrogen and C1-C4 alkyl;
R4d is C1-C4 alkyl;
R5 is selected from the group consisting of fluoro, —CN, —OH, —OR5a, =O, —CH2CO2R5b, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 hydroxyalkyl, C1-C4 hydroxyalkoxy, and C2-C6 alkoxyalkyl;
R5a is C1-C4 alkyl; and
R5b is C1-C4 alkyl;
n is an integer of 1 to 3.

### Claim 2 (depends on 1)

The compound of claim 1, or an enantiomer, a diastereomer, a racemate, a tautomer, a prodrug, a hydrate, a solvate or a pharmaceutically acceptable salt thereof, wherein L is —O—(CRaRb)nO—.

### Claim 3 (depends on 1)

The compound of claim 1, or an enantiomer, a diastereomer, a racemate, a tautomer, a prodrug, a hydrate, a solvate or a pharmaceutically acceptable salt thereof, wherein the compound is represented by the following formula (II)
where
R1 is selected from the group consisting of hydrogen, C1-C6 alkyl, and 5-6 membered heterocyclyl; wherein the C1-C6 alkyl of R1 is optionally substituted with 1 or 2 of R4;
R3 is selected from the group consisting of hydrogen, C1-C4 alkyl, C1-C4 haloalkyl, —P(O)(OR3d)2, —C(O)CHR3eNR3bR3c, —C(O)OH, —C(O)OR3a, —C(O)NR3bR3c, C3-C8 cycloalkyl, C5-C7 cycloalkenyl, 3-6 membered heterocyclyl, C5-C7 heterocycloalkenyl, C6 aryl, and 5-6 membered heteroaryl;
wherein the C3-C8 cycloalkyl, C6 aryl, 3-6 membered heterocyclyl, and 5-6 membered heteroaryl of R3, are optionally substituted with 1 or 2 of R5;
R3a is C1-C4 alkyl;
R3b and R3c are each independently selected from the group consisting of hydrogen, C1-C4 alkyl, C3-C6 cycloalkyl, and —CO2R3f;
R3d is selected from the group consisting of hydrogen, C1-C4 alkyl, and C2-C4 alkenyl;
R3e is selected from the group consisting of hydrogen and C1-C4 alkyl; wherein the C1-C4 alkyl of R3d is optionally substituted with 1 of R3g;
R3f is C1-C4 alkyl;
R3g selected from the group consisting of —OH, —SH, —SCH3, —NH2, —C(O)OH, —C(O)NH2, —NHC(NH)NH2, C6 aryl, and 5-9 membered heteroaryl; wherein the C6 aryl of R3g is optionally substituted with 1 of —OH;
R4 is selected from the group consisting of —OH, —OR4a, —C(O)NR4bR4c, and 5-6 membered heterocyclyl; wherein the 3-10 membered heterocyclyl of R4 is optionally substituted with 1 or 2 of C1-C4 alkyl;
R4a is C1-C4 alkyl; wherein the C1-C4 alkyl of R4a is optionally substituted with 1 of —Si(R4d)3;
R4b and R4c are each independently selected from the group consisting of H and C1-C4 alkyl;
R4d is C1-C4 alkyl;
R5 is selected from the group consisting of fluoro, —CN, —OH, —OR5a, ═O, —CH2CO2R5b, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 hydroxyalkyl, C1-C4 hydroxyalkoxy, and C2-C6 alkoxyalkyl;
R5a is C1-C4 alkyl; and
R5b is C1-C4 alkyl;
n is an integer of 1 to 3.

### Claim 4 (depends on 3)

The compound of claim 3, or an enantiomer, a diastereomer, a racemate, a tautomer, a prodrug, a hydrate, a solvate or a pharmaceutically acceptable salt thereof, wherein R3 is selected from the group consisting of hydrogen, C1-C4 alkyl, —P(O)(OR3d)2, and —C(O)CHR3eNR3bR3c.

### Claim 5 (depends on 4)

The compound of claim 4, or an enantiomer, a diastereomer, a racemate, a tautomer, a prodrug, a hydrate, a solvate or a pharmaceutically acceptable salt thereof, wherein R1 is selected from the group consisting of hydrogen and C1-C6 alkyl; wherein the C1-C6 alkyl of R1 is optionally substituted with 1 or 2 of R4; and R4 is selected from the group consisting of —OH and —OR4a.

### Claim 6 (depends on 5)

The compound of claim 5, or an enantiomer, a diastereomer, a racemate, a tautomer, a prodrug, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein the compound is

### Claim 7 (depends on 5)

The compound of claim 5, or an enantiomer, a diastereomer, a racemate, a tautomer, a prodrug, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof which is

### Claim 8 (depends on 1)

The compound of claim 1, or an enantiomer, a diastereomer, a racemate, a tautomer, a prodrug, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein
L is a bond; and
R3 is selected from the group consisting of hydrogen, fluoro, chloro, bromo, —CN, C1-C4 alkyl, C1-C4 haloalkyl, —OH, —OR3a, —NR3bR3c, —C(O)OH, —C(O)OR3a, —C(O)NR3bR3c, C3-C8 cycloalkyl, C5-C7 cycloalkenyl, 3-6 membered heterocyclyl, C5-C7 heterocycloalkenyl, C6 aryl, and 5-6 membered heteroaryl;
wherein the C3-C8 cycloalkyl, C6 aryl, 3-6 membered heterocyclyl, and 5-6 membered heteroaryl of R3, are optionally substituted with 1 or 2 of R5.

### Claim 9 (depends on 8)

The compound of claim 8, or an enantiomer, a diastereomer, a racemate, a tautomer, a prodrug, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein R1 is C1-C6 alkyl; wherein the C1-C6 alkyl of R1 is optionally substituted with 1 or 2 of R4; and R4 is selected from the group consisting of —OH, —OR4a, —C(O)NR4bR4c, and 5-6 membered heterocyclyl.

### Claim 10 (depends on 9)

The compound of claim 9, or an enantiomer, a diastereomer, a racemate, a tautomer, a prodrug, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein R1 is methyl.

### Claim 11 (depends on 10)

The compound of claim 10, or an enantiomer, a diastereomer, a racemate, a tautomer, a prodrug, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein R3 is selected from the group consisting of hydrogen, C1-C4 alkyl, C6 aryl, and 5-6 membered heteroaryl;
wherein the C6 aryl, and 5-6 membered heteroaryl of R3, are optionally substituted with 1 or 2 of R5; and
R5 is selected from the group consisting of —OH, —OR5a, C1-C4 alkyl, C1-C4 hydroxyalkyl, C1-C4 hydroxyalkoxy, and C2-C6 alkoxyalkyl.

### Claim 12 (depends on 1)

The compound of claim 1, or an enantiomer, a diastereomer, a racemate, a tautomer, a prodrug, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein
L is —O—(CRaRb)n—; and
R3 is selected from the group consisting of —CN, C3-C8 cycloalkyl, 3-6 membered heterocyclyl, C6 aryl, and 5-6 membered heteroaryl;
wherein the R3 C3-C8 cycloalkyl, C6 aryl, 3-6 membered heterocyclyl, and 5-6 membered heteroaryl, are optionally substituted with 1 or 2 of R5; and
R5 is selected from the group consisting of —OH, —CH2CO2R5b, C1-C4 alkyl, and C1-C4 hydroxyalkyl.

### Claim 13 (depends on 1)

The compound of claim 1, or an enantiomer, a diastereomer, a racemate, a tautomer, a prodrug, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, selected from the group consisting of
6-[1-(6-hydroxy-1,3-benzoxazol-2-yl)azetidin-3-yl]-3-[(1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-[1-(1,3-benzoxazol-2-yl)azetidin-3-yl]-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-[1-(6-chloro-1,3-benzoxazol-2-yl)azetidin-3-yl]-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-[1-(6-methyl-1,3-benzoxazol-2-yl)azetidin-3-yl]-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-[1-(5,6-dimethyl-1,3-benzoxazol-2-yl)azetidin-3-yl]-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-[1-(6-ethyl-1,3-benzoxazol-2-yl)azetidin-3-yl]-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-{1-[6-(cyclohex-1-en-1-yl)-1,3-benzoxazol-2-yl]azetidin-3-yl}-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-[1-(6-bromo-1,3-benzoxazol-2-yl)azetidin-3-yl]-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-[1-(6-cyclohexyl-1,3-benzoxazol-2-yl)azetidin-3-yl]-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
3-[(1-methyl-1H-pyrazol-4-yl)amino]-6-[1-(6-phenyl-1,3-benzoxazol-2-yl)azetidin-3-yl]pyrazine-2-carboxamide;
6-[1-(6-methoxy-1,3-benzoxazol-2-yl)azetidin-3-yl]-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-[1-(6-cyclopentyl-1,3-benzoxazol-2-yl)azetidin-3-yl]-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-{1-[6-(cyclopent-1-en-1-yl)-1,3-benzoxazol-2-yl]azetidin-3-yl}-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-{1-[6-(3,6-dihydro-2H-pyran-4-yl)-1,3-benzoxazol-2-yl]azetidin-3-yl}-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
3-[(1-methyl-1H-pyrazol-4-yl)amino]-6-{1-[6-(trifluoromethyl)-1,3-benzoxazol-2-yl]azetidin-3-yl}pyrazine-2-carboxamide;
methyl 2-(3-{6-carbamoyl-5-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazin-2-yl}azetidin-1-yl)-1,3-benzoxazole-6-carboxylate;
6-[1-(1,3-benzoxazol-2-yl)azetidin-3-yl]-3-[(1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
3-[(1-methyl-1H-pyrazol-4-yl)amino]-6-{1-[6-(oxolan-3-yl)-1,3-benzoxazol-2-yl]azetidin-3-yl}pyrazine-2-carboxamide;
6-{1-[6-(2,5-dihydrofuran-3-yl)-1,3-benzoxazol-2-yl]azetidin-3-yl}-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-{1-[6-(hydroxymethyl)-1,3-benzoxazol-2-yl]azetidin-3-yl}-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-(1-{6-[(1E)-3-hydroxy-3-methylbut-1-en-1-yl]-1,3-benzoxazol-2-yl}azetidin-3-yl)-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
2-(3-{6-carbamoyl-5-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazin-2-yl}azetidin-1-yl)-N,N-dimethyl-1,3-benzoxazole-6-carboxamide;
2-(3-{6-carbamoyl-5-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazin-2-yl}azetidin-1-yl)-1,3-benzoxazole-6-carboxylic acid;
6-{1-[6-(2-hydroxypropan-2-yl)-1,3-benzoxazol-2-yl]azetidin-3-yl}-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-[1-(6-hydroxy-1,3-benzoxazol-2-yl)azetidin-3-yl]-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-{1-[6-(3-hydroxy-3-methylbutyl)-1,3-benzoxazol-2-yl]azetidin-3-yl}-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-(1-{6-[(1E)-3-methoxyprop-1-en-1-yl]-1,3-benzoxazol-2-yl}azetidin-3-yl)-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-{1-[6-(cyclopropylmethoxy)-1,3-benzoxazol-2-yl]azetidin-3-yl}-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-{1-[6-(cyanomethoxy)-1,3-benzoxazol-2-yl]azetidin-3-yl}-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-(1-{6-[3-hydroxy-2-(hydroxymethyl)propyl]-1,3-benzoxazol-2-yl}azetidin-3-yl)-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
ethyl {[2-(3-{6-carbamoyl-5-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazin-2-yl}azetidin-1-yl)-1,3-benzoxazol-6-yl]oxy}acetate;
6-[1-(6-fluoro-1,3-benzoxazol-2-yl)azetidin-3-yl]-3-{[1-(oxan-4-yl)-1H-pyrazol-4-yl]amino}pyrazine-2-carboxamide;
6-[1-(6-fluoro-1,3-benzoxazol-2-yl)azetidin-3-yl]-3-{[1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-4-yl]amino}pyrazine-2-carboxamide;
6-[1-(1,3-benzoxazol-2-yl)azetidin-3-yl]-3-{[1-(2-methoxyethyl)-1H-pyrazol-4-yl]amino}pyrazine-2-carboxamide;
6-[1-(1,3-benzoxazol-2-yl)azetidin-3-yl]-3-{[1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-4-yl]amino}pyrazine-2-carboxamide;
6-{1-[6-(3-hydroxy-3-methylbutoxy)-1,3-benzoxazol-2-yl]azetidin-3-yl}-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-{1-[6-(3-hydroxypropyl)-1,3-benzoxazol-2-yl]azetidin-3-yl}-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-(1-{6-[(1E)-3-hydroxyprop-1-en-1-yl]-1,3-benzoxazol-2-yl}azetidin-3-yl)-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-{1-[6-(3-methoxypropyl)-1,3-benzoxazol-2-yl]azetidin-3-yl}-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-[1-(1,3-benzoxazol-2-yl)azetidin-3-yl]-3-({1-[2-(dimethylamino)-2-oxoethyl]-1H-pyrazol-4-yl}amino)pyrazine-2-carboxamide;
6-{1-[6-(2-methoxyethoxy)-1,3-benzoxazol-2-yl]azetidin-3-yl}-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
3-{[1-(2,3-dihydroxypropyl)-1H-pyrazol-4-yl]amino}-6-[1-(6-fluoro-1,3-benzoxazol-2-yl)azetidin-3-yl]pyrazine-2-carboxamide;
6-[1-(6-fluoro-1,3-benzoxazol-2-yl)azetidin-3-yl]-3-[(1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
3-({1-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-1H-pyrazol-4-yl}amino)-6-[1-(6-fluoro-1,3-benzoxazol-2-yl)azetidin-3-yl]pyrazine-2-carboxamide;
6-{1-[6-(2-amino-2-oxoethoxy)-1,3-benzoxazol-2-yl]azetidin-3-yl}-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-{1-[6-(2-hydroxy-2-methylpropoxy)-1,3-benzoxazol-2-yl]azetidin-3-yl}-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-(1-{6-[2-(dimethylamino)-2-oxoethoxy]-1,3-benzoxazol-2-yl}azetidin-3-yl)-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-{1-[6-(2-hydroxyethoxy)-1,3-benzoxazol-2-yl]azetidin-3-yl}-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
3-[(1-methyl-1H-pyrazol-4-yl)amino]-6-(1-{6-[(oxetan-3-yl)methoxy]-1,3-benzoxazol-2-yl}azetidin-3-yl)pyrazine-2-carboxamide;
6-(1-{6-[(3-hydroxycyclobutyl)methoxy]-1,3-benzoxazol-2-yl}azetidin-3-yl)-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-{1-[6-(2,3-dihydroxypropoxy)-1,3-benzoxazol-2-yl]azetidin-3-yl}-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-(1-{6-[(1-hydroxycyclobutyl)methoxy]-1,3-benzoxazol-2-yl}azetidin-3-yl)-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-(1-{6-[2-(3-hydroxyoxetan-3-yl)ethyl]-1,3-benzoxazol-2-yl}azetidin-3-yl)-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
3-[(1-methyl-1H-pyrazol-4-yl)amino]-6-{1-[6-(morpholine-4-carbonyl)-1,3-benzoxazol-2-yl]azetidin-3-yl}pyrazine-2-carboxamide;
6-(1-{6-[2-(dimethylamino)-2-oxoethyl]-1,3-benzoxazol-2-yl}azetidin-3-yl)-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-[1-(6-{[(2R)-1,4-dioxan-2-yl]methoxy}-1,3-benzoxazol-2-yl)azetidin-3-yl]-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
3-[(1-methyl-1H-pyrazol-4-yl)amino]-6-(1-{6-[2-oxo-2-(pyrrolidin-1-yl)ethoxy]-1,3-benzoxazol-2-yl}azetidin-3-yl)pyrazine-2-carboxamide;
6-(1-{6-[2-(methylamino)-2-oxoethyl]-1,3-benzoxazol-2-yl}azetidin-3-yl)-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-(1-{6-[3-hydroxy-2-(hydroxymethyl)propoxy]-1,3-benzoxazol-2-yl}azetidin-3-yl)-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-(1-{6-[(2,2-dimethyl-1,3-dioxan-5-yl)methoxy]-1,3-benzoxazol-2-yl}azetidin-3-yl)-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
N-tert-butyl-2-(3-{6-carbamoyl-5-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazin-2-yl}azetidin-1-yl)-1,3-benzoxazole-6-carboxamide;
2-(3-{6-carbamoyl-5-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazin-2-yl}azetidin-1-yl)-N-cyclopropyl-1,3-benzoxazole-6-carboxamide;
3-{[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]amino}-6-[1-(6-methyl-1,3-benzoxazol-2-yl)azetidin-3-yl]pyrazine-2-carboxamide;
3-{[1-(2-methoxyethyl)-1H-pyrazol-4-yl]amino}-6-[1-(6-methyl-1,3-benzoxazol-2-yl)azetidin-3-yl]pyrazine-2-carboxamide;
6-[1-(6-{[3-(hydroxymethyl)cyclobutyl]methoxy}-1,3-benzoxazol-2-yl)azetidin-3-yl]-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-(1-{6-[(3-hydroxyoxetan-3-yl)methoxy]-1,3-benzoxazol-2-yl}azetidin-3-yl)-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-[1-(6-{[(1S,2R)-2-(hydroxymethyl)cyclopropyl]methoxy}-1,3-benzoxazol-2-yl)azetidin-3-yl]-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-(1-{6-[(2R)-2-(hydroxymethyl)pyrrolidine-1-carbonyl]-1,3-benzoxazol-2-yl}azetidin-3-yl)-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
3-[(1-methyl-1H-pyrazol-4-yl)amino]-6-{1-[6-(3-phenylpropoxy)-1,3-benzoxazol-2-yl]azetidin-3-yl}pyrazine-2-carboxamide;
6-{1-[6-(3-hydroxy-2,2-dimethylpropoxy)-1,3-benzoxazol-2-yl]azetidin-3-yl}-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-(1-{6-[3-(dimethylamino)-3-oxopropyl]-1,3-benzoxazol-2-yl}azetidin-3-yl)-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
3-[(1-methyl-1H-pyrazol-4-yl)amino]-6-(1-{6-[3-oxo-3-(pyrrolidin-1-yl)propyl]-1,3-benzoxazol-2-yl}azetidin-3-yl)pyrazine-2-carboxamide;
6-(1-{6-[(2R)-2-(methoxymethyl)pyrrolidine-1-carbonyl]-1,3-benzoxazol-2-yl}azetidin-3-yl)-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
3-[(1-methyl-1H-pyrazol-4-yl)amino]-6-(1-{6-[2-oxo-2-(pyrrolidin-1-yl)ethyl]-1,3-benzoxazol-2-yl}azetidin-3-yl)pyrazine-2-carboxamide;
[2-(3-{6-carbamoyl-5-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazin-2-yl}azetidin-1-yl)-1,3-benzoxazol-6-yl]acetic acid;
6-[1-(6-{2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-2-oxoethyl}-1,3-benzoxazol-2-yl)azetidin-3-yl]-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-{1-[6-(2-hydroxy-2-methylpropyl)-1,3-benzoxazol-2-yl]azetidin-3-yl}-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-(1-{6-[(2R)-2-hydroxypropoxy]-1,3-benzoxazol-2-yl}azetidin-3-yl)-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
3-[(1-methyl-1H-pyrazol-4-yl)amino]-6-[1-(6-{[(3S)-oxolan-3-yl]oxy}-1,3-benzoxazol-2-yl)azetidin-3-yl]pyrazine-2-carboxamide;
6-[1-(6-{2-[(3S)-3-methoxypyrrolidin-1-yl]-2-oxoethyl}-1,3-benzoxazol-2-yl)azetidin-3-yl]-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-[1-(6-{2-[(2R)-2-(methoxymethyl)pyrrolidin-1-yl]-2-oxoethyl}-1,3-benzoxazol-2-yl)azetidin-3-yl]-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-(1-{6-[(1-methyl-2-oxopyrrolidin-3-yl)oxy]-1,3-benzoxazol-2-yl}azetidin-3-yl)-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-(1-{6-[2-(azetidin-1-yl)-2-oxoethoxy]-1,3-benzoxazol-2-yl}azetidin-3-yl)-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
{[2-(3-{6-carbamoyl-5-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazin-2-yl}azetidin-1-yl)-1,3-benzoxazol-6-yl]oxy}acetic acid;
6-[1-(6-methyl-1,3-benzoxazol-2-yl)azetidin-3-yl]-3-[(1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-(1-{6-[(2R)-2-(2-hydroxypropan-2-yl)pyrrolidine-1-carbonyl]-1,3-benzoxazol-2-yl}azetidin-3-yl)-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-(1-{6-[(1-methyl-2-oxopiperidin-3-yl)oxy]-1,3-benzoxazol-2-yl}azetidin-3-yl)-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
4-{[2-(3-{6-carbamoyl-5-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazin-2-yl}azetidin-1-yl)-1,3-benzoxazol-6-yl]oxy}-2-methylbutan-2-yl dihydrogen phosphate;
4-{[2-(3-{6-carbamoyl-5-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazin-2-yl}azetidin-1-yl)-1,3-benzoxazol-6-yl]oxy}-2-methylbutan-2-yl diprop-2-en-1-yl phosphate;
6-[1-(6-methyl-1,3-benzoxazol-2-yl)azetidin-3-yl]-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyridine-2-carboxamide;
6-(1-{6-[(2-hydroxycyclopentyl)oxy]-1,3-benzoxazol-2-yl}azetidin-3-yl)-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
3-[(1-methyl-1H-pyrazol-4-yl)amino]-6-(1-{6-[(1-methyl-1H-pyrazol-3-yl)methoxy]-1,3-benzoxazol-2-yl}azetidin-3-yl)pyrazine-2-carboxamide;
3-[(1-methyl-1H-pyrazol-4-yl)amino]-6-[1-(6-{2-oxo-2-[(2R)-2-(trifluoromethyl)pyrrolidin-1-yl]ethyl}-1,3-benzoxazol-2-yl)azetidin-3-yl]pyrazine-2-carboxamide;
3-[(1-methyl-1H-pyrazol-4-yl)amino]-6-(1-{6-[(5-methyl-1,3-thiazol-2-yl)methoxy]-1,3-benzoxazol-2-yl}azetidin-3-yl)pyrazine-2-carboxamide;
6-(1-{6-[2-(dimethylamino)-2-oxoethoxy]-1,3-benzoxazol-2-yl}azetidin-3-yl)-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyridine-2-carboxamide;
6-{1-[6-(3-hydroxy-3-methylbutoxy)-1,3-benzoxazol-2-yl]azetidin-3-yl}-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyridine-2-carboxamide;
6-[1-(6-hydroxy-1,3-benzoxazol-2-yl)azetidin-3-yl]-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyridine-2-carboxamide;
6-{1-[6-(2-hydroxy-2-methylpropoxy)-1,3-benzoxazol-2-yl]azetidin-3-yl}-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyridine-2-carboxamide;
6-(1-{6-[(5-methyl-1,3,4-oxadiazol-2-yl)methoxy]-1,3-benzoxazol-2-yl}azetidin-3-yl)-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-{1-[6-(2-cyclopropyl-2-oxoethoxy)-1,3-benzoxazol-2-yl]azetidin-3-yl}-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-{1-[6-(4-hydroxyphenyl)-1,3-benzoxazol-2-yl]azetidin-3-yl}-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-(1-{6-[4-(2-hydroxyethoxy)phenyl]-1,3-benzoxazol-2-yl}azetidin-3-yl)-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-(1-{6-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]-1,3-benzoxazol-2-yl}azetidin-3-yl)-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-(1-{6-[1-(2-methoxyethyl)-1H-pyrazol-4-yl]-1,3-benzoxazol-2-yl}azetidin-3-yl)-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
3-[(1-methyl-1H-pyrazol-4-yl)amino]-6-{1-[6-(1-methyl-1H-pyrazol-4-yl)-1,3-benzoxazol-2-yl]azetidin-3-yl}pyrazine-2-carboxamide;
3-[(1-methyl-1H-pyrazol-4-yl)amino]-6-(1-{6-[(1H-pyrazol-4-yl)methoxy]-1,3-benzoxazol-2-yl}azetidin-3-yl)pyrazine-2-carboxamide;
3-[(1-tert-butyl-1H-pyrazol-4-yl)amino]-6-{1-[6-(3-hydroxy-3-methylbutoxy)-1,3-benzoxazol-2-yl]azetidin-3-yl}pyrazine-2-carboxamide;
4-{[2-(3-{6-carbamoyl-5-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazin-2-yl}azetidin-1-yl)-1,3-benzoxazol-6-yl]oxy}-2-methylbutan-2-yl glycinate;
4-{[2-(3-{6-carbamoyl-5-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazin-2-yl}azetidin-1-yl)-1,3-benzoxazol-6-yl]oxy}-2-methylbutan-2-yl [(tert-butoxycarbonyl)amino]acetate;
6-{1-[6-(3-hydroxy-3-methylbutoxy)-1,3-benzoxazol-2-yl]azetidin-3-yl}-3-{[1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-4-yl]amino}pyrazine-2-carboxamide;
6-{1-[6-(3-hydroxy-3-methylbutoxy)-1,3-benzoxazol-2-yl]azetidin-3-yl}-3-[(1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-{1-[6-(3-hydroxy-3-methylbutoxy)-1,3-benzoxazol-2-yl]azetidin-3-yl}-3-[(1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
3-[(1-methyl-1H-pyrazol-4-yl)amino]-6-(1-{6-[(1-methyl-1H-pyrazol-4-yl)methoxy]-1,3-benzoxazol-2-yl}azetidin-3-yl)pyrazine-2-carboxamide;
6-(1-{6-[(1-methyl-1H-imidazol-4-yl)methoxy]-1,3-benzoxazol-2-yl}azetidin-3-yl)-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
3-[(1-methyl-1H-pyrazol-4-yl)amino]-6-{1-[6-(2-methyl-1,3-thiazol-5-yl)-1,3-benzoxazol-2-yl]azetidin-3-yl}pyrazine-2-carboxamide;
6-(1-{6-[4-(2-methoxyethoxy)phenyl]-1,3-benzoxazol-2-yl}azetidin-3-yl)-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-{1-[6-(2-ethoxypropan-2-yl)-1,3-benzoxazol-2-yl]azetidin-3-yl}-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
6-(1-{6-[(5-methoxypyrimidin-2-yl)oxy]-1,3-benzoxazol-2-yl}azetidin-3-yl)-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
3-[(1-methyl-1H-pyrazol-4-yl)amino]-6-(1-{6-[(pyridazin-3-yl)oxy]-1,3-benzoxazol-2-yl}azetidin-3-yl)pyridine-2-carboxamide;
6-[1-(6-{[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]methoxy}-1,3-benzoxazol-2-yl)azetidin-3-yl]-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
ethyl [4-({[2-(3-{6-carbamoyl-5-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazin-2-yl}azetidin-1-yl)-1,3-benzoxazol-6-yl]oxy}methyl)-1H-pyrazol-1-yl]acetate;
6-{1-[6-(1-methyl-1H-imidazol-4-yl)-1,3-benzoxazol-2-yl]azetidin-3-yl}-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
1-{[2-(3-{6-carbamoyl-5-[(1-methyl-1H-pyrazol-4-yl)amino]pyridin-2-yl}azetidin-1-yl)-1,3-benzoxazol-6-yl]oxy}-2-methylpropan-2-yl dihydrogen phosphate;
6-{1-[6-(2-cyano-2-methylpropoxy)-1,3-benzoxazol-2-yl]azetidin-3-yl}-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
1-{[2-(3-{6-carbamoyl-5-[(1-methyl-1H-pyrazol-4-yl)amino]pyridin-2-yl}azetidin-1-yl)-1,3-benzoxazol-6-yl]oxy}-2-methylpropan-2-yl glycinate;
4-{[2-(3-{6-carbamoyl-5-[(1-methyl-1H-pyrazol-4-yl)amino]pyridin-2-yl}azetidin-1-yl)-1,3-benzoxazol-6-yl]oxy}-2-methylbutan-2-yl dihydrogen phosphate;
4-{[2-(3-{6-carbamoyl-5-[(1-methyl-1H-pyrazol-4-yl)amino]pyridin-2-yl}azetidin-1-yl)-1,3-benzoxazol-6-yl]oxy}-2-methylbutan-2-yl glycinate;
6-{1-[6-(1-hydroxy-2-methylpropan-2-yl)-1,3-benzoxazol-2-yl]azetidin-3-yl}-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide;
ethyl 2-[2-(3-{6-carbamoyl-5-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazin-2-yl}azetidin-1-yl)-1,3-benzoxazol-6-yl]-2-methylpropanoate;
1-{[2-(3-{6-carbamoyl-5-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazin-2-yl}azetidin-1-yl)-1,3-benzoxazol-6-yl]oxy}-2-methylpropan-2-yl dihydrogen phosphate; and
1-{[2-(3-{6-carbamoyl-5-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazin-2-yl}azetidin-1-yl)-1,3-benzoxazol-6-yl]oxy}-2-methylpropan-2-yl glycinate.

### Claim 14 (depends on 13)

The compound of claim 13, or an enantiomer, a diastereomer, a racemate, a tautomer, a prodrug, a hydrate, a solvate or a pharmaceutically acceptable salt thereof, wherein the compound is 6-{1-[6-(2-hydroxy-2-methylpropoxy)-1,3-benzoxazol-2-yl]azetidin-3-yl}-3-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazine-2-carboxamide.

### Claim 15 (depends on 13)

The compound of claim 13, or an enantiomer, a diastereomer, a racemate, a tautomer, a prodrug, a hydrate, a solvate or a pharmaceutically acceptable salt thereof which is 1-{[2-(3-{6-carbamoyl-5-[(1-methyl-1H-pyrazol-4-yl)amino]pyrazin-2-yl}azetidin-1-yl)-1,3-benzoxazol-6-yl]oxy}-2-methylpropan-2-yl glycinate.

### Claim 16 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I) according to claim 1, or an enantiomer, a diastereomer, a racemate, a tautomer, a prodrug, a hydrate, a solvate or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.

### Claim at position 17

-20. (canceled)

### Claim 21 (depends on 1)

A method of treating or preventing a disease which is influenced by inhibition of Mer kinase, the method comprising administering to a mammals including humans in need thereof compositions comprising, as active ingredients, the compounds, or an enantiomer, a diastereomer, a racemate, a tautomer, a prodrug, a hydrate, a solvate or pharmaceutically acceptable salts thereof according to claim 1.

### Claim 22 (depends on 21)

The method of claim 21, wherein the disease which is influenced by inhibition of Mer kinase is cancer or immune-related diseases.

### Claim 23 (depends on 22)

The method of claim 22, wherein the cancer is selected from the group consisting of: glioma, gliosarcoma, anaplastic astrocytoma, medulloblastoma, lung cancer, small cell lung carcinoma, cervical carcinoma, colon cancer, rectal cancer, chordoma, throat cancer, Kaposi's sarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, colorectal cancer, endometrium cancer, ovarian cancer, breast cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, hepatic carcinoma, bile duct carcinoma, choriocarcinoma, seminoma, testicular tumor, Wilms' tumor, Ewing's tumor, bladder carcinoma, angiosarcoma, endotheliosarcoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland sarcoma, papillary sarcoma, papillary adenosarcoma, cystadenosarcoma, bronchogenic carcinoma, medullary carcinoma, mastocytoma, mesotheliorma, synovioma, melanoma, leiomyosarcoma, rhabdomyosarcoma, neuroblastoma, retinoblastoma, oligodentroglioma, acoustic neuroma, hemangioblastoma, meningioma, pinealoma, ependymoma, craniopharyngioma, epithelial carcinoma, embryonal carcinoma, squamous cell carcinoma, basal cell carcinoma, fibrosarcoma, myxoma, myxosarcoma, liposarcorna, chondrosarcoma, osteogenic sarcoma, leukemia and metastatic lesions secondary to these primary tumors.

### Claim 24 (depends on 22)

The method of claim 22, wherein the immune-related diseases are selected from the group consisting of infection and sepsis.
